​Why isn’t AI transforming biopharma as fast as we’d like?       

    The acceleration of artificial intelligence is arriving just in time for the biopharmaceutical industry.The global demand for innovative, effective treatments is growing faster than ever as the world’s largest drugmakers face intensifying regulatory, pricing, and political pressure. In this challenging environment, traditional industry processes must simply move faster.The good news: AI is starting to unlock the progress the industry needs. BMS and our peers are using AI tools to reinvent pharma right now, which is helping patients everywhere prevail over disease. Industry-wide, AI tools are reducing drug development time by as much as 10X and bringing greater efficiencies and momentum to the most time-consuming pharma process of all: clinical trials.STAT+ Exclusive StoryAlready have an account? Log in
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.Already have an account? Log inMonthly$39Totals $468 per year$39/monthGet StartedTotals $468 per yearStarter$30for 3 months, then $399/year$30 for 3 monthsGet StartedThen $399/yearAnnual$399Save 15%$399/yearGet StartedSave 15%11+ UsersCustomSavings start at 25%!Request A QuoteRequest A QuoteSavings start at 25%!2-10 Users$300Annually per user$300/yearGet Started$300 Annually per userView All Plans
To read the rest of this story subscribe to STAT+. SubscribeLog In